#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alagille syndrome Squamous cell carcinoma of the hypopharynx Ventricular fibrillation Piriformis syndrome B-cell lymphoma recurrent Paget's disease of the vulva Malignant fibrous histiocytoma Head and neck cancer Corneal neovascularisation Hypoparathyroidism Endometrial adenocarcinoma Candida infection Giant cell tumour of tendon sheath Mastocytosis Neovascular age-related macular degeneration More trials…

    Learn about Rare Diseases

    Idiopathic inflammatory myopathy – Treatment Nephroblastoma – Trials in Disease Hypereosinophilic syndrome – Life with Disease Short-bowel syndrome – Life with Disease Haemophilia A with anti factor VIII – Treatment Aicardi-Goutieres syndrome Idiopathic inflammatory myopathy – Trials in Disease Metachromatic leukodystrophy – Life with Disease Lymphangiosarcoma – Trials in Disease Hepatoblastoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Letermovir Dermatophagoides Pteronyssinus Posaconazole Vancomycin Ifinatamab Deruxtecan Retinol Acetate Dexmedetomidine Hydrochloride Tiemonium Methylsulphate POTASSIUM CLAVULANATE Acasunlimab Propranolol Hydrochloride LUNSEKIMIG Holcus Lanatus Pollen Extract Palonosetron Hydrochloride Varnimcabtagene Autoleucel Mifepristone Clonazepam RP2 ACICLOVIR SODIUM SEVABERTINIB More therapies…

    Learn about Your Condition

    Meningioma malignant Growth hormone deficiency Cutaneous lupus erythematosus Colon cancer Coeliac disease Impaired gastric emptying Transplantation complication Alpha-1 antitrypsin deficiency Angelman's syndrome Morning sickness Metastases to rectum Inflammation Vitiligo Metabolic disorder Primary hyperaldosteronism More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive breast cancer

  • Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • HER2 negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Palbociclib
    Austria France Hungary Italy Spain

  • Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Thyroid cancer
    • Transitional cell cancer of the renal pelvis and ureter
    • Malignant melanoma
    Investigated Drugs:
    • Jk08
    • Lenvatinib
    • Pembrolizumab
    Belgium Spain

  • Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    Investigated Drugs:
    • Giredestrant
    • Exemestane
    • Tamoxifen Citrate
    Germany Greece Italy Spain

  • Study to Improve Tolerance of Sacituzumab Govitecan with Loperamide and Filgrastim in Patients with Advanced Triple-Negative or Luminal Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Sacituzumab Govitecan
    • Filgrastim
    Spain

  • Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Goserelin
    • Letrozole
    Austria Belgium France Germany Hungary Ireland +4

  • Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer female
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Giredestrant
    • Anastrozole
    • Triptorelin
    France Germany Hungary Ireland Italy Spain +1
Previous Page
1 … 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!